Bone Density Protocol

Overview

Bone is a dynamic tissue in constant remodeling — osteoblasts build new bone while osteoclasts break down old bone. When resorption outpaces formation, bone density declines, progressing from normal bone to osteopenia (reduced density) to osteoporosis (significantly reduced density with increased fracture risk). This progression accelerates dramatically in post-menopausal women due to estrogen withdrawal, but also affects men and younger individuals under certain conditions (glucocorticoid use, hypogonadism, chronic illness, physical inactivity).

Peptide-based interventions for bone density center on teriparatide (recombinant PTH 1-34), the only FDA-approved anabolic bone agent that stimulates new bone formation rather than merely slowing resorption. Calcitonin, a naturally occurring peptide hormone, offers modest anti-resorptive and analgesic effects. Both are pharmaceutical-grade compounds requiring medical supervision — this protocol serves as an educational overview of their use within a comprehensive bone health framework.

For joint health approaches, see the Joint Support Protocol. For age-related health broadly, see the Over 40 Protocol.

Compounds Involved

Compound	Class	Primary Effects	Route	Typical Dose
Teriparatide (PTH 1-34)	Parathyroid hormone fragment	Osteoblast stimulation, new bone formation	SubQ	20 mcg daily
Calcitonin (salmon)	Peptide hormone	Anti-resorptive, analgesic for bone pain	Intranasal or SubQ	200 IU intranasal daily or 100 IU SubQ
Vitamin D3	Secosteroid hormone	Calcium absorption, bone mineralization	Oral	2,000–5,000 IU daily
Calcium citrate	Mineral	Bone mineral substrate	Oral	500–600 mg 2x daily
Vitamin K2 (MK-7)	Fat-soluble vitamin	Calcium trafficking to bone, osteocalcin activation	Oral	100–200 mcg daily

Teriparatide

Teriparatide is the recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34), marketed as Forteo. While continuous PTH elevation (as in hyperparathyroidism) is catabolic to bone, intermittent daily exposure to teriparatide produces an anabolic effect — it preferentially stimulates osteoblast activity, increasing bone formation rates, improving trabecular microarchitecture, and increasing cortical bone thickness.

Clinical trials have demonstrated significant increases in lumbar spine BMD (9–13% over 18 months), reduced vertebral fracture risk (65% reduction), and reduced non-vertebral fracture risk (53% reduction). Teriparatide is approved for use up to 24 months, after which patients transition to an anti-resorptive agent to maintain the gained bone density.

Calcitonin

Calcitonin is a 32-amino-acid peptide hormone normally produced by the thyroid gland's C-cells. Salmon calcitonin (used therapeutically due to higher potency than the human form) inhibits osteoclast activity, modestly reducing bone resorption. Its unique advantage is an analgesic effect for acute vertebral compression fractures — a property not shared by other osteoporosis treatments.

Calcitonin's bone density effects are modest compared to teriparatide and modern anti-resorptive agents (bisphosphonates, denosumab), positioning it primarily for its pain-relieving role in acute fracture settings.

Protocol Structure

Assessment and Diagnosis

Bone density management requires proper medical evaluation:

DEXA scan: Dual-energy X-ray absorptiometry is the standard for measuring bone mineral density (BMD). Results are expressed as:

• T-score: Comparison to peak bone mass of a healthy 30-year-old
  • Above -1.0: Normal
  • -1.0 to -2.5: Osteopenia
  • Below -2.5: Osteoporosis
  • Below -2.5 with fracture: Severe osteoporosis

Additional workup:

• Serum calcium, phosphate, alkaline phosphatase
• Vitamin D (25-OH) — target 40–60 ng/mL
• PTH (intact) — to rule out hyperparathyroidism
• Thyroid function
• Testosterone (in men)
• Bone turnover markers: CTx (resorption), P1NP (formation)
• FRAX score calculation (10-year fracture probability)

See Blood Work Monitoring for general laboratory guidance.

Foundation Protocol (All Patients)

Regardless of peptide use, these foundational interventions apply:

Nutritional support:

Supplement	Dose	Timing	Notes
Vitamin D3	2,000–5,000 IU	Morning with fat	Dose-adjust to blood levels (target 40–60 ng/mL)
Calcium citrate	500–600 mg	2x daily (separate doses)	Citrate preferred over carbonate for absorption
Vitamin K2 (MK-7)	100–200 mcg	With fat-containing meal	Directs calcium to bone; avoid with warfarin
Magnesium glycinate	300–400 mg	Evening	Supports vitamin D metabolism and bone structure
Boron	3 mg	Daily	Supports calcium and vitamin D metabolism

Weight-bearing exercise: The single most important non-pharmacological intervention for bone density.

• Impact activities: Walking, jogging, stair climbing, dancing, jumping
• Resistance training: 2–3 sessions per week targeting major muscle groups
• Balance training: Reduces fall risk (the proximate cause of most osteoporotic fractures)
• Avoid excessive flexion exercises if vertebral osteoporosis is present

Teriparatide Protocol (Medical Supervision Required)

Indication: Severe osteoporosis, osteoporosis with fracture history, inadequate response to anti-resorptive therapy, or glucocorticoid-induced osteoporosis.

Administration:

Parameter	Detail
Dose	20 mcg daily
Route	Subcutaneous injection (thigh or abdomen)
Timing	Once daily at a consistent time
Duration	Up to 24 months (FDA-approved maximum)
Storage	Refrigerated (2–8 degrees C); pen device

Monitoring schedule:

• Bone turnover markers (P1NP) at baseline, 3, and 12 months — P1NP increase confirms anabolic response
• Serum calcium at 1 and 6 months (teriparatide can transiently elevate calcium)
• DEXA scan at 12 and 24 months

Critical: Anti-resorptive sequencing After completing a teriparatide course, the gained bone density must be consolidated with an anti-resorptive agent (bisphosphonate or denosumab). Without this step, bone density rapidly returns to baseline. This transition should be planned with the prescribing physician before teriparatide initiation.

Calcitonin Protocol

Primary indication: Analgesic for acute vertebral compression fractures; secondary use for mild anti-resorptive effect.

Intranasal protocol:

• 200 IU daily (one spray in one nostril, alternating nostrils daily)
• Duration: Typically 2–4 weeks for acute fracture pain; up to 3–5 years for osteoporosis (though efficacy wanes)

Injectable protocol:

• 100 IU daily subcutaneously or intramuscularly for acute fracture pain
• Transition to intranasal after acute phase

Specific Populations

Post-Menopausal Women

Estrogen withdrawal accelerates bone loss at 2–3% per year for the first 5–7 years after menopause. Teriparatide is particularly effective in this population when combined with hormone optimization. See Female Considerations and Hormone Optimization Protocol.

Glucocorticoid-Induced Osteoporosis

Chronic glucocorticoid use (prednisone equivalent of 5+ mg/day for 3+ months) causes rapid bone loss primarily through osteoblast suppression. Teriparatide is the preferred agent because it directly stimulates the osteoblast pathway that glucocorticoids suppress.

Men with Osteoporosis

Male osteoporosis is underdiagnosed. Testosterone deficiency, hypogonadism, alcohol use, and glucocorticoid exposure are major risk factors. Testosterone optimization alongside teriparatide can be synergistic. See Hormone Optimization Protocol.

Important Considerations

• Prescription required: Teriparatide and calcitonin are prescription medications. This protocol requires medical supervision.
• Teriparatide contraindication: Not recommended for individuals with Paget's disease, unexplained elevation of alkaline phosphatase, prior radiation therapy to the skeleton, open epiphyses (children), or pre-existing hypercalcemia. The boxed warning regarding osteosarcoma risk (observed in rats with lifetime exposure) limits treatment duration to 24 months.
• Anti-resorptive sequencing is critical: Failure to follow teriparatide with an anti-resorptive agent negates much of the treatment benefit. This must be planned from the outset.
• Calcium and vitamin D are prerequisite: Teriparatide and calcitonin work best when calcium and vitamin D status are optimized. Deficiency blunts their effectiveness.
• Fall prevention: For individuals with osteoporosis, preventing falls is as important as improving bone density. Home safety assessment, balance training, vision correction, and medication review (for drugs causing dizziness) are essential.
• Monitoring: Regular DEXA scanning and bone turnover marker assessment guide treatment decisions.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.